Repare Therapeutics Inc.: restructuring charge — Repare Therapeutics cuts workforce 25%, focuses on four clinical programs, extends cash runway to H2 2026

Repare Therapeutics Inc.

Board approved reprioritization; workforce reduction of ~25%, mainly in preclinical group, affected employees notified Aug 28, 2024.
Expected one-time cash charges of $1.5M-$2.0M for termination benefits; substantially complete by Q3 2024.
Annual cost savings of ~$15M extend cash runway into second half of 2026.
Upcoming milestones: lunresertib+camonsertib data Q4 2024; potential registrational trial 2025; RP-3467 Phase 1 start Q4 2024.
RP-1664 Phase 1 LIONS trial ongoing; plans to advance into pediatric neuroblastoma Phase 1/2 after safety data.

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.95

Repare Therapeutics Inc. announced a restructuring with charges of termination benefits affecting workforce reduction (approximately 25%).

Type: restructuring
Charge: termination benefits
Affected area: workforce reduction
Headcount: approximately 25%

Exact text from the filing

the Company plans to reduce its overall workforce by approximately 25%, with the majority of the headcount reductions from the Company’s preclinical group, with affected employees notified on August 28, 2024. The Company expects to recognize total charges in connection with the Plan in the range of approximately $1.5 million to $2.0 million, consisting of one-time cash charges for termination benefits.

View on SEC.gov

Browse all restructurings & charges →

Source: SEC EDGAR

accession 0001193125-24-208814

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.